CEO Michael Bristow departs ARCA biopharma; COO Thomas Keuer named President

Oruka Therapeutics, Inc.

Dr. Bristow's employment and board membership ended April 3, 2024 by mutual agreement, not due to any disagreement.
Bristow receives lump sum of $370,000 (12 months salary plus $25K) and equity continues vesting under consulting agreement.
Thomas Keuer, COO since 2015, appointed President and principal executive officer effective April 3, 2024.
Keuer's appointment will end upon closing of the previously announced merger with Oruka Therapeutics.
Separation agreement includes standard release, confidentiality, non-disparagement, and arbitration clauses.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Thomas A. Keuer

President and principal executive officer

ORKA · Oruka Therapeutics, Inc.

Effective: 2024-04-03
Filed: April 4, 2024, 7:59 PM ET

the Board appointed Thomas A. Keuer, the Company’s Chief Operating Officer, to serve as ARCA’s President and principal executive officer.

Departed

Michael Bristow

President, Chief Executive Officer and Director

ORKA · Oruka Therapeutics, Inc.

Effective: 2024-04-03
Successor: Thomas A. Keuer
Filed: April 4, 2024, 7:59 PM ET

Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors (the “Board”) of ARCA have mutually agreed to conclude Dr. Bristow’s employment and service as a director, effective April 3, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas A. Keuer was appointed as President and principal executive officer at Oruka Therapeutics, Inc..

Action: appointed
Role: President and principal executive officer

Exact text from the filing

the Board appointed Thomas A. Keuer, the Company’s Chief Operating Officer, to serve as ARCA’s President and principal executive officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Bristow departed as President, Chief Executive Officer and Director at Oruka Therapeutics, Inc..

Action: concluded employment and service as director
Role: President, Chief Executive Officer and Director

Exact text from the filing

Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors (the “Board”) of ARCA have mutually agreed to conclude Dr. Bristow’s employment and service as a director, effective April 3, 2024.

View on SEC.gov

Oruka Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-041846

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.